Basit öğe kaydını göster

dc.contributor.authorEraksoy, Mefkure
dc.contributor.authorCoban, Arzu
dc.contributor.authorPETEK-BALCI, Belgin
dc.contributor.authorUlusoy, Canan
dc.contributor.authorKurtuncu, Murat
dc.contributor.authorTuzun, Erdem
dc.contributor.authorIcoz, Sema
dc.contributor.authorShugaiv, Erkingul
dc.contributor.authorTURKOGLU, Recai
dc.contributor.authorPehlivan, Munevver
dc.contributor.authorAkman-Demir, Gulsen
dc.date.accessioned2021-03-03T13:39:35Z
dc.date.available2021-03-03T13:39:35Z
dc.date.issued2015
dc.identifier.citationPETEK-BALCI B., Coban A., Shugaiv E., TURKOGLU R., Ulusoy C., Icoz S., Pehlivan M., Tuzun E., Akman-Demir G., Kurtuncu M., et al., "Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis", INTERNATIONAL JOURNAL OF NEUROSCIENCE, cilt.125, sa.5, ss.352-356, 2015
dc.identifier.issn0020-7454
dc.identifier.othervv_1032021
dc.identifier.otherav_35500daf-91bd-4c26-8bcb-fd5a02fce8a0
dc.identifier.urihttp://hdl.handle.net/20.500.12627/40034
dc.identifier.urihttps://doi.org/10.3109/00207454.2014.939747
dc.description.abstractBackground: In a previous study, we had evaluated short-term effects of interferon beta-1a (IFNB-1a) 44 mu g s.c. three times per week treatment on serum levels of IFN-gamma (IFNG), IL-23, IL-17, IL-10, IL-9, IL-4 and TGF-beta (TGFB) and found a reduction only in IL-17 and IL-23 levels after 2 months of treatment. Methods: Using the same multiple sclerosis (MS) cohort, we assessed the predictive value of early cytokine level changes (difference between 2nd month and baseline levels as measured by ELISA) on the efficacy of long-term IFNB-1a treatment. Results: The alteration in IFNG levels of patients without any relapse was statistically lower than that of patients having one or more relapses (p = 0.019, Student's t-test). When patients with or without expanded disability severity scale (EDSS) progression were compared, none of the cytokine level changes showed a significant difference between groups. IL-17 and IL-23 level changes did not predict relapse and EDSS progression in IFNB-1a-treated MS patients. Conclusion: Our results show that the predictive power of early IFNG measurement on relapse occurrence may potentially extend a time span of several years.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSinirbilim ve Davranış
dc.subjectNEUROSCIENCES
dc.titlePredictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis
dc.typeMakale
dc.relation.journalINTERNATIONAL JOURNAL OF NEUROSCIENCE
dc.contributor.departmentIstanbul Haseki Training & Research Hospital , ,
dc.identifier.volume125
dc.identifier.issue5
dc.identifier.startpage352
dc.identifier.endpage356
dc.contributor.firstauthorID1750


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster